Active, not recruitingPhase 2NCT00095784
Decitabine in Treating Patients With Myelofibrosis
Studying Primary myelofibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Olatoyosi M OdenikeUniversity of Chicago Comprehensive Cancer Center
- Intervention
- Decitabine(drug)
- Enrollment
- 21 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2004 – 2026
Study locations (14)
- University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
- Decatur Memorial Hospital, Decatur, Illinois, United States
- NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States
- Ingalls Memorial Hospital, Harvey, Illinois, United States
- Loyola University Medical Center, Maywood, Illinois, United States
- Illinois CancerCare-Peoria, Peoria, Illinois, United States
- Central Illinois Hematology Oncology Center, Springfield, Illinois, United States
- Southern Illinois University School of Medicine, Springfield, Illinois, United States
- Fort Wayne Medical Oncology and Hematology Inc-Parkview, Fort Wayne, Indiana, United States
- Northern Indiana Cancer Research Consortium, South Bend, Indiana, United States
- University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
- Oncology Care Associates PLLC, Saint Joseph, Michigan, United States
- Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
- Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00095784 on ClinicalTrials.govOther trials for Primary myelofibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07104799Momelotinib During and After HCT in MyelofibrosisMassachusetts General Hospital
- RECRUITINGPHASE3NCT07317700A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk MyelofibrosisChengdu Zenitar Biomedical Technology Co., Ltd
- RECRUITINGPHASE1, PHASE2NCT07128381Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)M.D. Anderson Cancer Center
- RECRUITINGPHASE1, PHASE2NCT06887803A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK InhibitorsiOnctura
- RECRUITINGPHASE1, PHASE2NCT07281781Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone MarrowUniversity of California, Irvine
- ACTIVE NOT RECRUITINGNCT07342712Clinical Trail to Evaluate the Effect of Long-term Treatment With Gecacitinib on Myelofibrosis and Gene Mutation LevelsFirst Affiliated Hospital of Zhejiang University
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT06909136A Study to Evaluate Safety , Efficacy and Pharmacokinetics of WJ01024 Tablets Combined With Ruxolitinib in Patients With MyelofibrosisSuzhou Junjing BioSciences Co., Ltd.
- RECRUITINGPHASE2NCT06770842Ropeginterferon Alfa 2b Plus Ruxolitinib for MyelofibrosisThe University of Hong Kong